Trial Profile
An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms REPEAT
- Sponsors GlaxoSmithKline; GSK
- 22 May 2014 New trial record